# R-MTX-zanbrutinib in Secondary CNS Lymphoma

> **NCT05398224** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 45 (estimated)

## Conditions studied

- Secondary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab

## Key facts

- **NCT ID:** NCT05398224
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-26
- **Primary completion:** 2024-02-26
- **Final completion:** 2024-05-26
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05398224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05398224, "R-MTX-zanbrutinib in Secondary CNS Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05398224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*